ReportWire

Tag: psilocybin

  • Legalization of ‘magic’ mushrooms back in the running

    [ad_1]

    BOSTON — More than a year after voters rejected a plan to legalize “magic” mushrooms, advocates have renewed the push on Beacon Hill for the use of psychedelic drugs again.

    The Joint Committee on Public Health voted to advance bipartisan legislation that would decriminalize the drug for adults 21 and older for treatment of post-traumatic stress and other ailments for veterans, law enforcement officers or others who are “professionally diagnosed” with a “qualifying” condition.

    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm%96 s6>@4C2E:44@?EC@==65 A2?6= 2=D@ 2AAC@G65 2 3:== E92E H@F=5 2FE9@C:K6 “E96C2AJ” 46?E6CD H96C6 AD:=@4J3:? 4@F=5 36 8:G6? E@ A2E:6?ED F?56C >65:42= DFA6CG:D:@?] x7 2AAC@G65[ E96 >62DFC6 H@F=5 2FE9@C:K6 2 A:=@E AC@8C2> H:E9 7:G6 D:E6D 24C@DD E96 DE2E6[ :?4=F5:?8 @?6 @? E96 }@CE9 $9@C6[ 244@C5:?8 E@ E96 =68:D=2E:@?]k^Am

    kAm%96 ?@?AC@7:E 8C@FA |2DDw62=:?8[ H9:49 25G@42E6D 7@C ADJ49656=:42DD:DE65 E96C2AJ[ AC2:D65 E96 4@>>:EE66 7@C 25G2?4:?8 E96 AC@A@D2=D[ D2J:?8 :E >2C6 E92E 2 q624@? w:== A2?6= 92D 2AAC@G65 =68:D=2E:@? E@ =682=:K6 E96 5CF8D]k^Am

    kAm“{2H 6?7@C46>6?E @77:46CD[ 7:CDE C6DA@?56CD[ 2?5 G6E6C2?D 42CCJ C62= EC2F>2[ 2?5 E@@ >2?J CF? @FE @7 @AE:@?D[” $2C<@ v6C86C:2?[ 2 (:?E9C@A A@=:46 =:6FE6?2?E H9@ DFAA@CED FD6 @7 DF49 5CF8 E96C2AJ[ D2:5 😕 2 DE2E6>6?E] “%9:D 6G:56?4632D65 AC@A@D2= 9@?@CD E9@D6 H9@ D6CG6[ 25G2?46D D4:6?46[ 2?5 7C66D FA A@=:46 C6D@FC46D 7@C H96C6 E96J 2C6 ?66565 >@DE]”k^Am

    kAmx? E96 a_ac 6=64E:@?D[ |2DD249FD6EED G@E6CD C6;64E65 “F6DE:@? c[ H9:49 42==65 7@C =682=:K:?8 “>28:4” >FD9C@@>D 2?5 @E96C ADJ49656=:4 4@>A@F?5D 7@C E96C2A6FE:4 AFCA@D6D 2?5 2FE9@C:K:?8 9@>6 8C@H:?8] %96 >62DFC6 72:=65 3J 2 G@E6 @7 dfT E@ cbT[ 244@C5:?8 E@ 6=64E:@? C6DF=ED]k^Am

    kAm%96 32==@E BF6DE:@? H2D 324<65 3J E96 (2D9:?8E@?[ s]r]32D65 }6H pAAC@249 A@=:E:42= 24E:@? 4@>>:EE66[ H9:49 DFAA@CE65 D:>:=2C :?:E:2E:G6D 😕 ~C68@? 2?5 r@=@C25@[ H96C6 AD:=@4J3:? 😀 =682=] %96 8C@FA C2:D65 2?5 DA6?E >:==:@?D @7 5@==2CD @? 25G6CE:D:?8 E@ DH2J G@E6CD]k^Am

    kAmq24<6CD @7 =682=:K:?8 E96 5CF8[ H9:49 :?4=F56 >:=:E2CJ G6E6C2?D 2?5 7@C>6C A@=:46 @77:46CD[ 2C8F6 E96C6 😀 8C@H:?8 6G:56?46 E92E AD:=@4J3:? 2?5 @E96C ADJ49656=:4 DF3DE2?46D 42? 96=A 😕 EC62E:?8 ADJ49@=@8:42= 5:D@C56CD DF49 2D A@DEEC2F>2E:4 DEC6DD 5:D@C56C 2?5 2?I:6EJ]k^Am

    kAm%96 &]$] u@@5 2?5 sCF8 p5>:?:DEC2E:@? C646?E=J 2FE9@C:K65 2 “3C62A2?:6D]k^Am

    kAmqFE AD:=@4J3:? 😀 DE:== :==682= F?56C 7656C2= =2H[ 4=2DD:7:65 2D 2 $4965F=6 ` 5CF8 F?56C E96 &]$] r@?EC@==65 $F3DE2?46D p4E[ 2=@?8 H:E9 {$s[ 96C@:? 2?5 @E96C 5CF8D[ H:E9 ?@ 2446AE65 >65:42= FD6D]k^Am

    kAm|65:42= 6IA6CED 42FE:@? 282:?DE =682=:K:?8 2 5CF8 E92E 42? =625 E@ ADJ49@D:D[ D2J:?8 :E H@F=5 ;6@A2C5:K6 AF3=:4 962=E9 2?5 D276EJ]k^Am

    kAm%92E 92D?’E DE@AA65 2 92?57F= @7 |2DD249FD6EED 4@>>F?:E:6D[ :?4=F5:?8 $2=6>[ p>96CDE 2?5 r2>3C:586[ 7C@> 2AAC@G:?8 A=2?D E@ 564C:>:?2=:K6 D>2== 2>@F?ED @7 AD:=@4J3:? 2?5 2FE9@C:K6 :ED FD6 7@C E96C2AJ]k^Am

    kAm%96 ADJ49656=:4 AC@A@D2=D 7246 =@?8 @55D @? q624@? w:==[ H96C6 =68:D=2E:G6 =6256CD 92G6 366? C6=F4E2?E E@ E2<6 FA AC6G:@FD D:>:=2C >62DFC6D] q@E9 3:==D H@F=5 ?665 E@ 36 2AAC@G65 3J E96 7F== DE2E6 w@FD6 @7 #6AC6D6?E2E:G6D 2?5 $6?2E6 367@C6 =2?5:?8 @? v@G] |2FC2 w62=6J’D 56D< 7@C 4@?D:56C2E:@?]k^Am

    kAmk6>mr9C:DE:2? |] (256 4@G6CD E96 |2DD249FD6EED $E2E69@FD6 7@C }@CE9 @7 q@DE@? |65:2 vC@FAUCDBF@jD ?6HDA2A6CD 2?5 H63D:E6D] t>2:= 9:> 2E k2 9C67lQ>2:=E@i4H256o4?9:?6HD]4@>Qm4H256o4?9:?6HD]4@>k^2m]k^6>mk^Am

    [ad_2]

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Magic mushrooms for postpartum depression treatment? Florida researchers running trials

    [ad_1]

    Researchers at the University of South Florida are conducting clinical trials to explore the potential of psilocybin, a compound found in magic mushrooms, as a treatment for postpartum depression and other mental health disorders.Tracey Tee, founder and CEO of Moms on Mushrooms, said, “We’ve greatly misjudged and mis-prioritized the mental health of mothers in general and we’ve gotten a lot of it wrong.”Her group educates women about magic mushrooms and psilocybin, focusing on how they can help mothers dealing with trauma or depression. Tee emphasized the potential of microdosing and magic mushrooms as an emerging solution, although she acknowledged it may not be suitable for everyone. “Studying it for postpartum in particular is like a no-brainer for me,” she said.Health researchers at the University of South Florida are investigating whether psilocybin can help treat major depressive disorders, postpartum depression, and other conditions.Dr. Ryan Wagoner, who was involved with the research, said, “What we are eventually trying to move towards are these medications that can be Food and Drug Administration-approved just like any medication you might take.” Wagoner said if psilocybin’s medical properties are proven to outweigh its risks, it could be reclassified and approved as a medication. “If you can show that the substance does have a medical property that’s valuable to it and outweighs any sorts of risks, suddenly we can move what schedule it’s on and get it approved to be a medication just like anything else,” Wagoner said.Researchers say psilocybin works by targeting serotonin receptors in the brain, enhancing sensory input and potentially disrupting neural networks involved in depression. They are exploring the use of smaller doses to activate serotonin receptors without causing unwanted side effects. “What if we use a smaller dose. What if we use a dose that activates the serotonin receptor but doesn’t cause as much of those side effects that we’re not looking for,” Wagoner said.Tee believes the stigma around magic mushrooms should be replaced with a view of them as a medical treatment. “The idea is that you’re not high and that it’s mimicking and still working in the brain and body in the same way that a large dose journey does, that’s like transformative effects, but we are doing it in smaller amounts over time incrementally so that you are able to go about your day,” she said. She added that psilocybin should be paired with other treatments. “It really needs to be paired with something because it’s not a passive magic pill in the same way an antidepressant is; you really want to work with the medicine,” Tee said.The National Institutes of Health reports that approximately 30% of patients with major depressive disorder have treatment-resistant depression. A Johns Hopkins study found that two doses of psilocybin produced rapid and large reductions in depressive symptoms. “You actually have to put into practice, and so that is why we do clinical trials to first detect if there are side effects we weren’t expecting,” Wagoner said. They are investigating whether psilocybin offers benefits beyond existing medications.”Is this something real that’s going on in the brain that’s different or better than some of the medications we already have on the market,” Wagoner said.Tee expressed optimism about the role of psychedelics in mental health treatment, saying, “I think there’s a really beautiful place for psychedelics to slide in and support a lot of people without a lot of damage we’re seeing being caused by other modalities.”Magic mushrooms remain illegal in Florida, classified as a Schedule 1 controlled substance at both the state and federal levels. Possession of psilocybin mushrooms is a felony, with significant fines, probation, and potential prison time. Florida has also banned mushroom spores, despite them not containing psilocybin. Wagoner said clinical trials will continue, with more data and research being collected to potentially achieve FDA approval in the future.

    Researchers at the University of South Florida are conducting clinical trials to explore the potential of psilocybin, a compound found in magic mushrooms, as a treatment for postpartum depression and other mental health disorders.

    Tracey Tee, founder and CEO of Moms on Mushrooms, said, “We’ve greatly misjudged and mis-prioritized the mental health of mothers in general and we’ve gotten a lot of it wrong.”

    Her group educates women about magic mushrooms and psilocybin, focusing on how they can help mothers dealing with trauma or depression. Tee emphasized the potential of microdosing and magic mushrooms as an emerging solution, although she acknowledged it may not be suitable for everyone.

    “Studying it for postpartum in particular is like a no-brainer for me,” she said.

    Health researchers at the University of South Florida are investigating whether psilocybin can help treat major depressive disorders, postpartum depression, and other conditions.

    Dr. Ryan Wagoner, who was involved with the research, said, “What we are eventually trying to move towards are these medications that can be Food and Drug Administration-approved just like any medication you might take.”

    Wagoner said if psilocybin’s medical properties are proven to outweigh its risks, it could be reclassified and approved as a medication.

    “If you can show that the substance does have a medical property that’s valuable to it and outweighs any sorts of risks, suddenly we can move what schedule it’s on and get it approved to be a medication just like anything else,” Wagoner said.

    Researchers say psilocybin works by targeting serotonin receptors in the brain, enhancing sensory input and potentially disrupting neural networks involved in depression.

    They are exploring the use of smaller doses to activate serotonin receptors without causing unwanted side effects.

    “What if we use a smaller dose. What if we use a dose that activates the serotonin receptor but doesn’t cause as much of those side effects that we’re not looking for,” Wagoner said.

    Tee believes the stigma around magic mushrooms should be replaced with a view of them as a medical treatment.

    “The idea is that you’re not high and that it’s mimicking and still working in the brain and body in the same way that a large dose journey does, that’s like transformative effects, but we are doing it in smaller amounts over time incrementally so that you are able to go about your day,” she said.

    She added that psilocybin should be paired with other treatments.

    “It really needs to be paired with something because it’s not a passive magic pill in the same way an antidepressant is; you really want to work with the medicine,” Tee said.

    The National Institutes of Health reports that approximately 30% of patients with major depressive disorder have treatment-resistant depression.

    A Johns Hopkins study found that two doses of psilocybin produced rapid and large reductions in depressive symptoms.

    “You actually have to put into practice, and so that is why we do clinical trials to first detect if there are side effects we weren’t expecting,” Wagoner said.

    They are investigating whether psilocybin offers benefits beyond existing medications.

    “Is this something real that’s going on in the brain that’s different or better than some of the medications we already have on the market,” Wagoner said.

    Tee expressed optimism about the role of psychedelics in mental health treatment, saying, “I think there’s a really beautiful place for psychedelics to slide in and support a lot of people without a lot of damage we’re seeing being caused by other modalities.”

    Magic mushrooms remain illegal in Florida, classified as a Schedule 1 controlled substance at both the state and federal levels.

    Possession of psilocybin mushrooms is a felony, with significant fines, probation, and potential prison time.

    Florida has also banned mushroom spores, despite them not containing psilocybin.

    Wagoner said clinical trials will continue, with more data and research being collected to potentially achieve FDA approval in the future.

    [ad_2]

    Source link

  • Why religious groups are pushing for psychedelic drugs as sacrament

    [ad_1]

    Texas passed a landmark law in June 2025, supported by former Gov. Rick Perry, that allocates $50 million to support research on ibogaine, one of the most powerful psychedelics, for treating opioid addiction and treatment-resistant PTSD. Arizona passed a similar law in May, funding research on ibogaine’s effectiveness for treating veterans and those with traumatic brain injuries…

    [ad_2]

    Pardis Mahdavi | The Conversation

    Source link

  • Psilocybin — the drug in ‘magic mushrooms’ — could see federal restrictions loosened

    [ad_1]

    Regulation of psilocybin — the “magic” substance in psychedelic mushrooms — has been a hot-button issue for Californians in recent years, but repeated attempts by state lawmakers to allow medical use of the substance have floundered.

    Now it seems change may come at the federal level.

    The U.S. Department of Health and Human Services is weighing a petition sent earlier this month by the Drug Enforcement Administration to review the scientific evidence and consider easing restrictions.

    Psilocybin is currently classified as a Schedule I narcotic, the most restrictive category under federal law, reserved for drugs “with a high potential for abuse” and “no currently accepted medical use.” The DEA is considering moving psilocybin into the less restrictive Schedule II tier, which includes drugs that are considered addictive or dangerous — including fentanyl and cocaine — but also have medical value.

    Past efforts to allow for therapeutic use of psilocybin have largely stalled in the face of official intransigence and lack of political will, including in California, where state lawmakers’ efforts to decriminalize psilocybin and other psychedelic substances have failed multiple times.

    Despite strict prohibition under both state and federal law, psilocybin is widely available and growing in popularity for both recreational and therapeutic purposes.

    Illegal cannabis dispensaries across Southern California openly sell actual psilocybin mushrooms, as well as dodgy chocolates and gummies that often purport to contain the substance but instead contain only synthetic versions. In recent decades, a growing body of research has found that psilocybin can be beneficial in treating mental health conditions including depression, anxiety and substance use disorder.

    The issue of psychedelic access is high on the agenda of Robert F. Kennedy Jr., Trump’s controversial and conspiracy-minded secretary of Health and Human Services. Kennedy has signaled support in the past for expanding access to some hallucinogens in medical settings for treatment of mental health disorders.

    Kennedy’s agency directed all inquiries to the DEA, which said in an email that it is “unable to comment on or confirm scheduling actions.”

    The DEA sent the psilocybin petition after a drawn-out legal battle led by Dr. Sunil Aggarwal. For about five years, Aggarwal, co-director of the Advanced Integrative Medical Science Institute in Seattle, has been seeking a means to legally obtain and administer psilocybin to ailing and aging patients for care during the final phases of their lives.

    Kathryn L. Tucker, a lawyer for Aggarwal, wrote a letter to the DEA this month that said he “continues to provide care to patients with advanced and terminal cancer who could benefit greatly from psilocybin assisted therapy, enabling them to experience a more peaceful dying process.”

    “The science supports movement to schedule II; such placement will enable access under Right to Try laws, which contemplate early access to promising new drugs for those with life-threatening conditions,” Tucker wrote.

    Aggarwal filed a lawsuit after his 2020 petition to reschedule psilocybin was denied. A federal panel dismissed the suit, but the move toward rescheduling continues now that the DEA has officially forwarded his petition to the Department of Health and Human Services.

    But some researchers and other experts caution against moving too fast to expand access.

    Dr. Steven Locke, a former Harvard Medical School psychiatry professor, wrote in an email that the question of whether psilocybin has any medical applications “remains controversial.” A past president of the American Psychosomatic Society, Locke has studied rare conditions such as Hallucinogen Persisting Perception Disorder, which cause symptoms akin to long-lasting “bad trips” in a small percentage of people who use psilocybin mushrooms and other psychedelics.

    “There is little evidence from good-quality studies to support claims for the efficacy of the use of psilocybin for the treatment of any medical disorders,” said Locke. “The reclassification should be contingent on a careful review.”

    [ad_2]

    Connor Sheets

    Source link

  • Question 4: Should the state legalize psychedelic mushrooms?

    Question 4: Should the state legalize psychedelic mushrooms?

    [ad_1]

    BOSTON — Supporters of psychedelic mushrooms are urging voters to approve a referendum legalizing the hallucinogenic drug for “therapeutic” use, but critics argue the move would jeopardize public health and safety and fuel a gray market.

    Question 4 would, if approved, decriminalize psilocybin and other psychedelics and allow adults 21 and older to use the drugs under supervision at licensed centers. It would also allow people to grow their own mushrooms at home and give the drugs to others.

    Unlike the legalization of recreation cannabis in 2016, Question 4 if approved would not authorize retail sales of psychedelics. Psychedelics sold at therapeutic facilities would be subject to the state’s 6.25% sales tax and a new 15% excise tax.

    Adults 21 and older would be allowed to grow, possess and use psychedelics. A home-grow provision in the proposal would allow people to cultivate psychedelic mushrooms in their home in a 144-square-foot area, according to the referendum’s wording.

    The group Massachusetts for Mental Health Options, which has cleared several hurdles to put the question before voters, frames the effort as a way to help treat mental illness, citing studies showing the promise of psilocybin as a therapeutic drug.

    Backers of the referendum, which include military veterans and former police officers, argue there is growing body of evidence that psilocybin and other psychedelic substances can help in treating psychological disorders such as post-traumatic stress disorder and anxiety.

    “For years, I struggled with PTSD and depression … Psychedelic medicine was a breakthrough for me,” said Emily Oneschuk, a Navy veteran and outreach director for the group, said in recent TV ad urging voters to approve the measure. “It helped me embrace life again.”

    But opponents, including medical experts, argue that legalizing a drug that can lead to psychosis would jeopardize public health and safety.

    Chris Keohan, spokesman for the opposition group Coalition For Safe Communities, said major concern about question for Question 4 is that it wouldn’t allow cities and towns to opt out of hosting “therapy” centers. He said opponents are also alarmed about the “bedroom size” grow area that would be allowed for psychedelics under the home-grow provision.

    “We’re not challenging the medicinal benefits for the people that genuinely need the help,” he said. “But this was written to enable for-profit facilities to open up.”

    Another concern for opponents is the cost of psychedelic therapy, which would not be covered by insurance and would likely be beyond what most people in the state can afford to pay for out-of-pocket health care costs, he said. The ballot question does not set a cap on how much can be charged for the therapeutic treatment.

    “I’d like to know how many people in the state of Massachusetts are going through the painful issues that they talk about can afford $750 to $3,500 per visit,” Keohan said. “They are providing false hope to the people that need it the most.”

    He said another concern is that the referendum includes several kinds of psychedelic compounds, in addition to psilocybin, which create major health risks for patients. That includes mescaline, derived from the peyote cactus, and ibogaine, a drug that comes from the roots of the African shrub iboga, which is known to cause cardiac arrests and seizures.

    “Massachusetts voters aren’t stupid and they know when they’re being sold a bill of goods, and that’s what this is,” Keohan said.

    The ballot question is backed by the Washington, D.C.-based New Approach political action committee, which has supported similar initiatives in Oregon and Colorado, where psilocybin is legal. The group has raised and spent millions of dollars on advertising to sway voters on the referendum.

    The U.S. Food and Drug Administration has authorized “breakthrough therapy” status for the psychedelic drug for the purposes of clinical trials being conducted by private research companies.

    But psilocybin is still illegal under federal law, classified as a Schedule 1 drug under the U.S. Controlled Substances Act along with LSD, heroin and other drugs, with no accepted medical uses.

    A handful of Massachusetts communities, including Salem, Amherst and Cambridge, have approved plans to decriminalize small amounts of psilocybin and authorize its use for therapy.

    A legislative committee that reviewed the proposal concluded that the primary goals of the referendum — licensure and decriminalization — would likely “undercut each other by creating two separate systems for the use of psychedelic substances.” The lawmakers said that could fuel black market sales of the hallucinogenic drug.

    “The petition would both create a system of state-licensed and taxed therapeutic facilities on the one hand and, on the other, decriminalize the cultivation, possession, and distribution of a variety of hallucinogenic and psychoactive substances,” lawmakers wrote in a report on the proposal.

    A report by Tufts University’s Center for State Policy Analysis echoed those concerns.

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    [ad_2]

    By Christian M. Wade | Statehouse Reporter

    Source link

  • How To Make Mushroom Chocolate at Home

    How To Make Mushroom Chocolate at Home

    [ad_1]

    Mary Ekundayo

    Posted by Mary Ekundayo on 03/21/2024 in Alternative Medicine

    How To Make Mushroom Chocolate at HomeHow To Make Mushroom Chocolate at Home

    What better way to transform the not-so-tasty magic mushroom into a sweet chocolatey delight than by making mushroom chocolate? 

    If you’ve ever eaten shrooms, then you can attest that they have a rather unpleasant flavor and texture. Of course, this doesn’t in any way affect their medicinal value, but people can be discouraged from benefiting from their worth because of their taste.

    In this article, we’ll show you how to use chocolate to make magic mushrooms into a delicious wonder. The most exciting part? You can get it done at home!

    Health Benefits of Chocolate

    One major ingredient in chocolate that is responsible for its health benefits is cocoa. Pure cocoa creates similar results in our body and mind as magic mushrooms, however, at lower levels. As such, the effects of chocolate can include: 

    • Reducing stress levels: Cocoa influences our serotonin system to reduce stress levels, which causes a greater feeling of tranquility.
    • Combating depression: Because it activates oxytocin (or the love hormone) in our brains, chocolate functions as a natural antidepressant.
    • Stimulating the central nervous system (CNS): Chocolate contains theobromine, which improves blood flow in the muscles. This, in turn, enhances alertness, cognitive function, and the delivery of oxygen to the brain. 

    Chocolate + Magic Mushroom: How Safe Is It?

    Chocolate made from pure cocoa functions as mild monoamine oxidase inhibitors or MAOIs. Many antidepressants are MAOIs, which prevent the removal of serotonin and dopamine from the brain. As opposed to mixing stronger MAOIs with shrooms, which can have some unpleasant results, chocolate is safe to use with magic mushrooms. 

    Most of the chocolates you’ll find at stores today are made from refined cocoa. To get the best mushroom chocolate, it is ideal to use some raw cocoa.

    Before Getting Started: A Note On Psilocybin

    The psilocybin in mushrooms doesn’t do well with heat. In fact, it begins to break down around 70°C, which can ultimately ruin its effect. Irrespective of what you want to cook or prepare, you shouldn’t go beyond this temperature.

    The best way to preserve psilocybin is to cook any ingredient that needs heat first and add mushrooms after the heat is gone. So, whether it’s tea you want to add your shrooms into, ensure the water is cooled off first. Similarly, for mushroom chocolate, it’s best to melt the chocolate and then add shrooms when the heat is gone.

    How To Make Magic Mushroom Chocolate

    Once you have your ingredients set, magic mushroom chocolate is pretty easy to make. Here are the resources you’ll need and how to get it done.

    Ingredients and Equipment

    • Cracker-dry magic mushrooms
    • Bars of your favorite chocolate
    • Raw cocoa (optional)
    • A glass or metal bowl
    • A large saucepan
    • Stirring spoon
    • A coffee grinder or sharp knife
    • Baking tray (non-stick)
    • Candy or alcohol thermometer (optional)

    Instructions

    1. Cut or grind the mushrooms into smaller pieces. The smaller they are, the better.
    2. Break your chocolate into smaller chunks and place them in the glass or metal bowl.
    3. To melt the chocolate, pour some water into the saucepan. Then, transfer the bowl with the chocolate into the pan, and ensure there’s about an inch or more space between the water and the base of the bowl.
    4. Bring the saucepan to boil over low heat so that the steam will cause the chocolate in the bowl to melt. You can aid the process by gently stirring the chocolate with a stirring spoon.
    5. Alternatively, you can melt the chocolate by placing the bowl in a microwave and heating it at intervals of 30 seconds so it doesn’t get burnt. 
    6. After melting the chocolate, allow it to cool down to below 70°C. You can use a candy or alcohol thermometer to ascertain the temperature.
    7. Once the chocolate is below 70°C (and still liquid), add the ground mushrooms and the cocoa powder.
    8. Stir the mixture until the content is evenly distributed.
    9. Scoop out the mix in molds onto the baking tray and place in the fridge to cool.
    10. Once it’s cool and solid, your mushroom chocolate is ready to eat!

    Tip: You can also make magic truffles chocolate by following the same process for mushroom chocolate. Additionally, any extra flavoring you want to add should be oil-based and melted separately so it’s easy to mix.

    Carefully Dose Your Mushroom Chocolate

    In practice, it is a bit difficult to tell the exact dose of shrooms in your chocolate. However, a good rule of thumb is to use one dose of mushrooms for a portion of mushroom chocolate. You can then scale it up based on the number of times and the number of people who would eat the shroom chocolate.

    If it’s your first time trying this recipe out, it’s advisable to go even lower with your first dose. Over time, you’ll know the dosage that best suits you.

    Mushroom Chocolate Effects  

    Magic mushrooms are known for the euphoric high they cause. As such, you should expect the psychedelic and relaxing effect of the shrooms after eating the chocolate.

    However, it typically takes about 30 minutes for the effect to kick in. In fact, some varieties of mushrooms can take up to 45 minutes to 1 hour before you feel anything. Therefore, it is best to wait at least an hour before eating more magic chocolate.

    How Long Do Magic Mushrooms Last?

    The truth is that the lifecycle of mushroom chocolate depends largely on how you store the chocolate. If you seal it and store it in a cool and dark place, it can last up to a year while retaining the psychoactive properties of the shrooms.

    Fun fact: While chocolate could have a funny taste with time, it never really spoils.

    Go Create Magic!

    Making magic mushroom chocolate is an easy, delicious, and rewarding journey to embark on. Moreover, the raw cocoa further enhances the stimulating effect of the shrooms.

    Note that this recipe is just a foundation. You can explore the addition of other ingredients like nuts and dried fruits. So, if you love chocolate and also want to try magic mushrooms, what are you waiting for? Go create magic today.

    [ad_2]

    Source link

  • Exploring the Potential of Psychedelics for Autism 

    Exploring the Potential of Psychedelics for Autism 

    [ad_1]

    Mary Ekundayo

    Posted by Mary Ekundayo on 03/28/2024 in Alternative Medicine

    Exploring the Potential of Psychedelics for AutismExploring the Potential of Psychedelics for Autism

    Autism Spectrum Disorder is a very serious developmental issue that affects and impairs someone’s ability to communicate and interact. Fortunately, researchers have identified that there might be a positive relationship between psychedelics and autism. 

    In order to fully understand this relationship, the Marijuana Doctors team will attempt to examine Autism Spectrum Disorder and how psychedelics can affect it. 

    What is Autism Spectrum Disorder (ASD)? 

    According to various research reports, Autism Spectrum Disorder (ASD) is a developmental disability that is caused by a difference in the brain. Autism Spectrum Disorder can either be genetic or could be caused by several unknown factors acting together. 

    Autism Spectrum Disorder can start manifesting before the age of 3, and most people with ASD often have issues communicating and interacting with people. People with ASD can either have restrictive or repetitive behaviors, and their way of life may be different from those without ASD. 

    Psychedelic Effects 

    Psychedelics belong to a drug class known as hallucinogenics. These classes of drugs have been saddled with the effect of triggering non-ordinary mental states, which can provide a change in perception, thoughts, emotions, and auditory senses. 

    The most common examples of these classes of drugs are LSD (lysergic acid diethylamide), psilocybin, and ayahuasca. A lot of research has been done regarding the use of psychedelic substances to aid personal and mental development like anxiety, depression, and post-traumatic stress disorder (PTSD), and the results have been fairly positive. 

    Psychedelics and Autism 

    Although psychedelic drugs have been used to treat personal and mental illnesses or disorders, their use in treating autism has been limited. However, researchers are trying to branch out fully into this area to extensively realize the connection and safety implications of psychedelics and their effect on autism. 

    Benefits Of Psychedelics On Autism Spectrum Disorder 

    Based on the limited data on the use of psychedelics on autism, we will be taking you through a few of the most significant benefits of psychedelics on autism. 

    It Can Help Modulate Serotonin Receptors in The Brain 

    Serotine is a neurotransmitter that actively works in regulating human emotion, mood, cognition, and other physiological functions. Psychedelics have been said to help modulate similar neurotransmitters, such as serotonin receptors, in the brain. 

    The interaction of the psychedelic with the serotonin receptors in the brain can help autistic people who have similar symptoms to those of depression, anxiety, and post-traumatic stress disorder (PTSD). 

    Neurochemical Effects 

    With the little research available on psychedelics, reports on it have shown that they tend to promote neuroplasticity. This is the ability of the brain to reorganize and form new neural connections on its own. These neural connections can explain the therapeutic feeling gotten from people who have conditions like anxiety, depression, and PTSD. 

    This will also have the potential to give this therapeutic effect to people suffering from autism. 

    It Helps Increase Brain Connectivity 

    The frequent use of psychedelics has been shown to help increase the functional connection between all of the brain regions that seem not to be strongly connected. This may help people with autism experience a more holistic and strong interconnected experience of consciousness. 

    Possible Risks and Side Effects of Psychedelics on Autism 

    Before anyone decides to use psychedelic substances to treat autism, the first thing that needs to be done is to research possible risks and side effects associated with it. 

    Here are some of the possible side effects associated with psychedelics:

    Psychological or Mental Distress 

    The use of psychedelics can alter or induce one’s emotional and mental health. The drug aims to work on these emotional experiences, and can sometimes intensify their feelings of confusion or anxiety. This might even be more dangerous for people with autism because they tend to be extremely sensitive in these areas. 

    It Can Cause a Change in Communication Patterns 

    Many people with autism already struggle with speech disorders and sometimes find it difficult to communicate effectively with others. Although one of the benefits of psychedelics on autism is to help improve communication skills, it can also be an issue. 

    Psychedelics work differently for everyone. For some, it helps with communication. For others, it can further increase their difficulty in expressing themselves.

    Increased Sensory Perception 

    The psychedelic effect works to help effectively heighten your sensory organs. This might cause a huge change in auditory and visual perception, which can be pretty overwhelming for people with autism because of their sensitivity to sensory stimuli. 

    Due to the limited research on the effects of psychedelics on autism, there’s nothing much we can offer at this point, but it is advisable to approach psychedelics with caution. Additionally, it should be under professional supervision. 

    Interactions Between Psychedelics and Other Drugs 

    As a person with autism, your first step before using psychedelic substances is to check how well they interact with the drugs that have been earlier prescribed to you by your medical professionals. 

    You must visit your doctor to be sure of how well your autism drugs and psychedelic drugs work together, as some interactions might have very negative effects. 

    The Future of Psychedelics and Autism 

    For now, we are only exposed to limited data on the research of psychedelics and how they particularly affect Autism Spectrum Disorder. However, moving forward, we are hoping that there will be more comprehensive research surrounding this topic. 

    This research will further focus on how exactly it works while monitoring their symptoms and the duration it takes to work. While this is important, making sure that these psychedelic treatments are made accessible and affordable to people suffering from autism should be of utmost importance. 

    There also needs to be proper sensitization of the public about autism. Providing information about autism, its causes, and how psychedelics have been developed to help tackle it to the public will further help healthcare professionals in their professional capacities. It can assist with how they approach people with autism spectrum disorder moving forward. 

    Final Words 

    Studies about psychedelics and their effects on autism are still in the early stages. A few reports have shown that there might just be a very positive correlation between them. However, approaching it needs a little caution. While evaluating the potential benefits, you should also take a look at the potential side effects to make sure that you’re on the right path. 

    Continuous research on this subject will be beneficial to individuals who have Autism Spectrum Disorder, and this might help improve their way of life making it easier for them to function among other people. 

    [ad_2]

    Source link

  • Blue Honey: What Is It and How To Make It

    Blue Honey: What Is It and How To Make It

    [ad_1]

    Mary Ekundayo

    Posted by Mary Ekundayo on 03/15/2024 in Alternative Medicine

    Blue Honey: What Is It and How To Make ItBlue Honey: What Is It and How To Make It

    If you have taken magic mushrooms before, then you can attest to their not-so-pleasant raw taste. However, did you know that there are ways to make your shroom experience more enjoyable? For example, you can brew them like tea to drink, cook them with other foods, or grind them to swallow in magic capsules.

    One other tasty solution for your mushrooms is to transform them into blue honey, also called magic mushroom honey. In this article, you’ll learn all you need to know about this sweet psychedelic delight. The most exciting part? You’ll learn how to make a jar or two for yourself. Let’s get started.

    What Is Blue Honey?

    In simple terms, blue honey refers to honey that is infused with psilocybin. Compared with other techniques of extracting psilocybin from psychedelic mushrooms, this honey is easy to prepare, store, and dose.

    The reason it’s called blue is because, more often than not, when it is prepared, one part of it turns blue. The prevailing explanation behind this phenomenon is that psilocin, the compound behind the psychedelic effect of psilocybin, turns blue whenever it’s exposed to oxygen.

    If this theory is true, the implication is that the bluer your honey, the less psychoactive it might be. The same can be said for mushroom tea. It turns into a more vibrant blue the longer the liquid is exposed to air.

    How To Make Blue Honey

    Blue honey is simple to make as long as you have mushrooms are available. Check out our guide on how to prepare yours in the comfort of your home.

    Ingredients

    • Honey (preferably runny honey)
    • Dried magic mushrooms
    • Coffee grinder or knife
    • Airtight glass jar

    Directions

    1. Grind the shrooms into fine powder to make it easy for the honey to extract the psilocybin.
    2. Pour in the honey and ground mushroom powder into the glass jar in alternate layers. You can start with a layer of magic mushrooms, then a layer of honey. Repeat this process until the ingredients are exhausted.
    3. Next, transfer the layered mixture into a bowl and mix thoroughly.
    4. Pour the mixture back into the glass jar, then store it in a cool and dry place for at least one month.

    How To Enjoy Blue Honey

    Blue honey is very versatile and can be enjoyed in so many ways. You can: 

    • Add it to your toast.
    • Add it to your cup of tea. However, ensure your hot tea cools down before adding your blue honey.
    • Add it to other foods that you normally take with honey.
    • Simply eat it on its own. 

    Benefits Of Blue Honey

    If you are skeptical about exploring blue honey, there are some upsides of this magic food that might change your mind. It tastes delicious, it is easy to microdose on blue honey, and its preparation doesn’t require any cooking. Its versatility makes it easy to add to a number of foods so you can choose your own adventure every time. 

    Other Things To Note About Blue Honey

    Following these practices will help you end up with high-quality magic mushroom honey:

    • Ensure you use thoroughly dry mushroom stems to make your honey last longer.
    • For a more potent result, use more magic mushroom powder.
    • The psilocybin potency is typically preserved for up to many years without degradation if it’s kept away from light, heat, and oxygen.

    When Not To Take Blue Honey

    The blue honey psilocybin experience is nothing short of powerful and rewarding. Nonetheless, you might need to steer clear of taking it if you are:

    • on prescription pills
    • experiencing anxiety, depression, or other forms of mental stress
    • pregnant or breastfeeding

    How To Know Your Blue Honey Dosage

    The psychedelic effect of your blue honey largely depends on the amount of the mushroom you use, so the potency will be different for different people. As such, you can only determine your dosage by consuming the honey in bits and monitoring its effect on you. Start small and work your way up to larger amounts. 

    After figuring this out once, you can tell how powerful your magic mushroom honey is and the safest quantity to take per time.

    Alternative Ways to Consume Mushrooms

    As you read through this article, you must have noticed that we mentioned other ways to make your magic mushroom less boring to consume. After trying out our blue honey recipe, feel free to explore the other options we have outlined below.

    Magic Mushrooms Capsules

    With handy tools like a capsule machine, empty capsules, and ground shrooms, you’ll get these done in no time. Pour the magic mushroom powder into the empty capsules and close them up using the capsule machine. Voila! Your capsules are ready to be swallowed. You can typically dose these out more accurately as well. 

    Magic Mushrooms Edibles

    You can add magic mushrooms to almost any food that you eat. However, the catch is never to add it during any cooking process to avoid destroying the psilocybin. For example, you can add shrooms to your sauces and toppings after cooking them. Other popular options include adding it to ice cream or a peanut butter and jelly sandwich. 

    Magic Mushrooms Tea

    Do the following to make a cup of shroom tea:

    • Cut your magic mushrooms into small pieces and throw them into a pan of hot water.
    • Let the shrooms simmer for about 20 minutes. Don’t let the water boil to preserve the psychedelic effect of the plant.
    • Strain out the mixture into a cup to get rid of the mushroom stems. 
    • Feel free to add ginger, honey, and other additives you normally put in your tea.

    Lemon Tek

    Lemon tekking is an increasingly popular way to consume shrooms. Some people claim it makes them stronger, but there is little scientific evidence to support this as of yet. Regardless, it’s a tasty and easy way to take shrooms. Here’s how it’s prepared:

    • Add some lemon juice to a glass cup.
    • Pour your ground magic mushrooms into the cup.
    • Let the mixture sit for some time.
    • Add some water and gulp down the drink. 

    Double Delight

    Magic mushroom honey is the perfect blend of the tasty honey world and the psychedelic adventure. Instead of dealing with bone-dry shroom stems, you get to enjoy them in a delicious way.

    However, just as you would do with any other psychedelic, ensure you start small when consuming blue honey to avoid overdosing. A good practice is to start with one teaspoon and slowly increase the quantity based on your tolerance level.

    Enjoy!

    [ad_2]

    Source link

  • Poison center calls spiked after magic mushrooms were decriminalized

    Poison center calls spiked after magic mushrooms were decriminalized

    [ad_1]

    Calls to poison control centers spiked across the U.S. for adolescents and young adults exposed to the hallucinogen psilocybin, according to our analysis of data from 55 U.S. poison centers between 2013 and 2022. The calls increased after 2019 when psilocybin was decriminalized and legalized in several cities and states…

    [ad_2]

    Christopher P. Holstege and Rita Farah | The Conversation

    Source link

  • Mushroom dreams: Arizona lawmakers signal support for psilocybin use

    Mushroom dreams: Arizona lawmakers signal support for psilocybin use

    [ad_1]

    Arizona lawmakers have mushrooms on their mind.

    A bipartisan group of state senators signaled its broad support for a bill making its way through the legislature that legalizes psilocybin mushrooms under controlled, therapeutic settings. Studies have found that psilocybin can be useful in treating mental illnesses such as post-traumatic stress disorder and depression.

    The Arizona Senate passed Senate Bill 1570 on Feb. 29 by a vote of 24-4, with two members not voting. The bill moved to the House and was assigned to the Heath and Human Services Committee on Monday.

    Two weeks before the Senate vote, the Senate Health and Services Committee voted unanimously to recommend approval of the bill. Republican state Sen. Thomas “T.J.” Shope, the principal sponsor of the bill, led the hearing.

    “We just had a press conference on this issue out on the lawn that was probably the most well-attended press conference we’ve had all session long,” Shope said during the Feb. 13 meeting. “That tells me there is a desire to explore what treatment for PTSD looks like other than what is already available to Arizonans.”

    Psychedelic-assisted therapy is not limited to treatment for PTSD. The Arizona Department of Health Services was allotted $5 million in 2023 from the state’s $18 billion budget to conduct clinical trials on the effects of psilocybin mushrooms in treatment for autoimmune disorders, depression, anxiety, substance abuse and chronic pain, among other conditions. The $5 million in funding came after a bill that would have provided $30 million for natural psilocybin research failed to pass.

    A quirk in the funding, though, means that researchers would need to spend grants from the $5 million by the end of the state’s budget year, which is June 30. Supporters of the funding said that’s not enough time. A legislative fix extending the deadline to 2026 — House Bill 2105 — has stalled in the House.

    click to enlarge

    The medical benefits of magic mushrooms are getting serious attention by Arizona lawmakers.

    Daniel Berehulak / Getty Images

    ‘Psilocybin not typically a substance of dependence’

    SB 1570 would establish the Arizona Psilocybin Advisory Board, tasked with approving training programs to license health care professionals in psilocybin-assisted therapy centers. The bill calls for appointments to the APAB to be made by the end of this year.

    According to the bill, the Arizona DHS can begin accepting applications to license health care professionals on Jan. 1, 2026. Only medical doctors, nurse practitioners, physician assistants and naturopaths would be allowed to prescribe psilocybin.

    “During my time as a psychiatric provider, I’ve become acutely aware of how limited our treatment options are for effective mental health interventions, both pharmaceutical and psychotherapeutic,” said Jennifer Montjoy, an Arizona psychiatric nurse practitioner, during the Senate committee meeting in February.

    “Roughly half of patients treated for a major depressive disorder and PTSD do not respond to available treatment options,” she added. “They’re considered treatment-resistant.”

    During the meeting, Montjoy noted that psychedelic-assisted therapy usually consists of one or two sessions. It is meant to be a short-term treatment, in contrast with some forms of talk therapy or prescription medications.

    “Though psilocybin is used recreationally, due to the intensity and duration of high-dose experiences, it’s not typically a substance of dependence,” she said. “It’s also not a substance of ongoing, repeated misuse.”

    Montjoy considers psilocybin a nonaddictive intervention, and she mentioned its potential application for treating anxiety disorders, obsessive-compulsive disorder, end-of-life anxiety and substance misuse, in addition to PTSD. She addressed fears of possible dependence by saying that withdrawal from the use of psychedelics has not been observed in studies.

    Other states have been early adopters of mushroom use. Oregon passed a measure in 2020 that decriminalized hard drugs and allowed psilocybin mushrooms to be used in therapeutic settings. And in 2022, Colorado decriminalized the possession, growing and use of five natural psychedelic substances, including psilocybin. The measure allows for the use of psychedelic mushrooms in licensed facilities by late this year.

    click to enlarge psilocybin mushroom

    A psilocybin mushroom displayed at a growing competition in Denver last November.

    Evan Semón

    Arizona’s opportunity to be a pioneering state

    Jimmy Nguyen is the Colorado-based co-founder of Psychedelic Passage, a site that provides information and referrals to people interested in healing through psychedelics. Both Nguyen and Montjoy acknowledge that embracing the use of psychedelics will not be a magic cure for PTSD or depression, and it isn’t for everyone, though it does provide another tool in addition to traditional treatment options.

    “Arizona has the opportunity to be one of those pioneering states that say, ‘Hey, how does this work for Arizona?’” Nguyen said. “‘How does this work for us and the people who live here?’”

    Nguyen, who has experience both as a facilitator and as a “journeyer” — a user of psychedelics for healing purposes — cited a number of factors to think about when determining whether psychedelics are the right treatment option. These include family attitudes as well as life and medical history.

    When vetting facilitators for his organization, Nguyen looks for certifications and experience with trauma-informed care, as well as first responder skills. Personal experience with psychedelics and a background of caring for clients or journeyers also are important, Nguyen said. A facilitator’s demeanor can affect treatment.

    ”Some psychedelic experiences are full of bliss, love, connection with all and joy,” Nguyen said. “Some others are much more challenging and difficult to navigate through. I find that in those difficult experiences, there can be a lot of learning, a lot of catharsis and potential for growth.”

    Nguyen said clients must feel comfortable; they need to trust the person sitting across from them. “These are experiences that bring up a lot of vulnerable topics,” he added. “These are experiences where individuals can dive really deeply into themselves.”

    Nguyen encourages the use of psychedelic-assisted therapy alongside traditional forms of therapy or medication. He also noted that psilocybin has helped him grapple personally with the inevitability of suffering. The main root cause for most suffering comes from either a feeling of “not enoughness,” he said, or from an individual’s lack of a meaningful relationship with themselves.

    Psychedelics provide an opportunity to dive into the core causes, Nguyen said. “Maybe it’s not addressing the symptom,” he said. “But maybe it’s actually addressing the core reason for why those symptoms exist in the first place.”

    [ad_2]

    Noah Cullen

    Source link

  • Research Shows Science Behind Psychedelics, Psychotherapy’s Ability To Cause Quick Brain Changes | High Times

    Research Shows Science Behind Psychedelics, Psychotherapy’s Ability To Cause Quick Brain Changes | High Times

    [ad_1]

    Psychedelic-assisted psychotherapy merges the principles of talk therapy with the effects of psychedelics. Many people seeking help with depression, PTSD, anxiety, or other mental health conditions have tried one or the other. 

    Some notable research includes looking at the use of psilocybin, one of the psychoactive components of magic mushrooms, to treat anxiety experienced by patients with metastatic cancers. Other studies spotlight the use of psychedelic therapy to help patients receiving hospice care cope with feelings of depression and hopelessness. 

    Such studies suggest that people, especially those with terminal illnesses like cancer, experience profound psychological transformations in a single six-hour session involving psilocybin when combined with psychotherapy. This dual approach results in a drastic improvement in mood and acceptance of one’s situation. 

    And now, neuroscientists understand more about how and why these positive outcomes occur. Research indicates that forming new neural connections facilitates assimilating new skills, memories, and attitudes, PsyPost reports. Known as arborization, this process is comparable to the branching of trees, which it’s named after. This happens when neurons create new pathways. This neural growth is crucial in fostering changes in cognition and emotional responses.

    Scientists use a method known as two-photon microscopy to examine this phenomenon in living cells. This technique lets them monitor the development and retraction of spines on neurons. Prepare for some science, reader: These neuron spines comprise one part of the synapses, essential for facilitating communication between neurons. 

    Scientists widely believed that lasting spine formation in the brain required continuous and repetitive mental effort. But, new research from Yale suggests that it could happen quickly and even in one dosage. The scientists observed swift spine formation in the frontal cortex of mice after just a single dose of psilocybin. Obviously, the mice did not receive therapy and integration. But, the study showed that mice administered with psilocybin exhibited around a 10% increase in spine formation. These changes were not fleeting; they were noted one day post-treatment and then persisted for over a month.

    Psychoactive compounds mainly alter brain activity by interacting with receptors on neural cells. Among these, the serotonin receptor 5HT, commonly targeted by traditional antidepressants, exists in multiple subtypes. So, there’s more than one way to use them to prompt positive change. Psychedelics like DMT (the key ingredient in ayahuasca) activate a specific receptor subtype known as 5-HT2A. Researchers believe this receptor also plays a crucial role in facilitating hyperplastic states, periods when the brain undergoes rapid changes. 

    The 5-HT2A receptors, which DMT activates, are found not only on the surface of neuron cells but also within the neuron itself. The famous internal 5-HT2A receptor is key to igniting the rapid changes in neuronal structure. Serotonin is unable to penetrate the cell membrane, which is why people don’t experience hallucinations when taking antidepressants like Prozac or Zoloft (much to many readers taking the mood-elevators distaste). In contrast, psychedelics can cross the cell boundary and influence the internal 5-HT2A receptor, promoting the growth of dendrites and an increase in spine formation.

    Besides being the active component in ayahuasca, as readers may know, DMT is also a molecule naturally produced in mammalian brains — including humans. 

    The fact that our brains make DMT suggests that human neurons can generate their own ‘psychedelic’ molecules (albeit in minuscule amounts). It’s conceivable that the brain employs its own endogenous DMT as a mechanism for adaptation, such as forming dendritic spines on neurons to embed crucial mental states. Ideally, a patient would use therapy in conjunction with these molecular changes for the best possible outcome when seeking help for a mental health condition. 

    While the brain only makes small amounts of DMT, you may have heard that when we die, there’s a massive burst of it, explaining some of what folks claim to see during near-death experiences. The hypothesis that the brain releases DMT in large quantities at death is a favorite in the psychedelic community; however, it remains a hypothesis without solid scientific backing. Research in this area is challenging not only to any drug laws but also to the ethical and practical difficulties of studying the brain at the moment of death.

    However, the psychedelic community must remember that bad trips do happen, and that’s not something you want happening to you or someone that you love in the final days of your life. As PsyPost points out, in “These Precious Days,” a collection of essays by Ann Patchett, she recounts an experience of consuming mushrooms with a friend who was battling pancreatic cancer. Her friend underwent a spiritual and transformative experience, emerging with a heightened connection to her loved ones. Patchett, however, describes her experience differently, likening it to spending eight hours in a dark, nightmarish scenario, akin to being in a cauldron of lava at the Earth’s core, where she felt as if she was constantly battling snakes. 

    While there’s evidence that psychedelic therapy can do miraculous work, explained by even more miraculous science, even all the Yale researchers and psychonauts in the world can’t prevent with complete certainty the risk of battling snakes in a cauldron of lava at the Earth’s core. 

    [ad_2]

    Sophie Saint Thomas

    Source link

  • New Research Exploring Psychedelics as a Treatment for Anxiety in Cancer Patients | High Times

    New Research Exploring Psychedelics as a Treatment for Anxiety in Cancer Patients | High Times

    [ad_1]

    The use of psychedelics as a treatment for serious mental health conditions continues to gain traction as multiple studies focus on the psychological symptoms commonly experienced by cancer patients. In one study, researchers at the University of Washington are exploring the use of psilocybin, one of the psychoactive components of magic mushrooms, to treat anxiety experienced by patients with metastatic cancers. Other research focuses on using psychedelic therapy to help patients receiving hospice care cope with demoralization. 

    In a separate study at the Center for Psychedelic Medicine at the New York University (NYU) School of Medicine, researchers are conducting a clinical trial using psilocybin-assisted therapy to treat existential distress in patients with advanced-stage cancer in collaboration with colleagues at the University of Colorado. Dr. Xiaojue Hu, a psychiatrist and researcher at NYU’s Center for Psychedelic Medicine, noted that the study “is building on the same work in this area originally done at NYU in the 2010s.” 

    “Now, there are many other studies using psilocybin in cancer patients, including a study using psilocybin in combination with multidisciplinary palliative care to treat demoralized cancer survivors with chronic pain going on at Emory University,” she told SurvivorNet.

    Hu explained that psychedelic-assisted therapy could be a more sustainable and effective treatment for cancer patients than other commonly prescribed alternatives including antidepressants. 

    “From the psilocybin research on depression alone, we’ve seen clinically significant impact from just one or two doses of psilocybin in conjunction with therapeutic support that can last up to 14 months for some patients,” said Hu. “This is in contrast to antidepressants, which people have to take on a daily basis for potentially years, with a risk of relapse when the meds are tapered off.”

    Psilocybin And MDMA For Mental Health

    Clinical research and other studies into psychedelics such as psilocybin and MDMA have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, PTSD, substance misuse disorders and anxiety. In January, a California biopharmaceutical company announced positive results from a clinical trial testing MDMA as a treatment for PTSD. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer.

    Although the research is promising, Hu said that psychedelic-assisted therapy does not work for everyone and that further research is needed to confirm the efficacy and safety of the treatment.

    “Psychedelics aren’t a panacea or miracle cure for anxiety and depression, as there’s still much that’s unknown about them and there’s always the potential for adverse effects, like with any treatment,” Dr. Hu said.

    Hu added that research has focused on using psychedelic treatments in conjunction with multiple sessions that integrate more traditional forms of therapy.

    “Most of the research is also done when psychedelics, such as psilocybin, are used in the context of therapeutic support with usually two therapists, which can include up to three sessions of preparation and three sessions of integration afterwards,” she said. “So the results are not completely due to the physiologic effects of psilocybin alone, in my opinion, but must be taken into context with the therapeutic and environmental support that’s also offered.”

    Hu also noted that psychedelic-assisted therapy is conducted in a tightly controlled environment because the set and setting in which a patient receives the treatment can have an impact on its success.

    “We typically don’t expect different results if someone took their Lexapro [an antidepressant] in different moods, with different people, or in different environments, but we definitely can when it involves psychedelics,” she said.

    While the research continues, the use of psychedelics to treat serious mental health conditions such as anxiety and depression has yet to achieve approval from health regulators. The U.S. Department of Health and Human Services projects that the Food and Drug Administration will eventually approve MDMA and psilocybin mental health treatments, according to a letter from the department in May 2022. In 2017, the FDA granted MDMA-assisted therapy Breakthrough Therapy designation, indicating that the therapy is a significant improvement over existing treatments. 

    The Multidisciplinary Association for Psychedelic Studies (MAPS) predicts that an application to use MDMA to treat PTSD will be submitted to the FDA at some point in 2023, and approval could come as early as 2024. But so far, MDMA-assisted therapy has not been approved by any regulatory agency and the safety and efficacy of MDMA-assisted therapy for the treatment of PTSD have not been firmly established.

    “MDMA and psilocybin have the most clinical research and legal momentum behind them right now, with psilocybin already being legalized in Oregon and Colorado and MDMA phase III trials recently being completed,” said Hu.

    [ad_2]

    A.J. Herrington

    Source link

  • Psychedelics Open Your Brain. You Might Not Like What Falls In.

    Psychedelics Open Your Brain. You Might Not Like What Falls In.

    [ad_1]

    If you’ve ever been to London, you know that navigating its wobbly grid, riddled with curves and dead-end streets, requires impressive spatial memory. Driving around London is so demanding, in fact, that in 2006 researchers found that it was linked with changes in the brains of the city’s cab drivers: Compared with Londoners who drove fixed routes, cabbies had a larger volume of gray matter in the hippocampus, a brain region crucial to forming spatial memory. The longer the cab driver’s tenure, the greater the effect.

    The study is a particularly evocative demonstration of neuroplasticity: the human brain’s innate ability to change in response to environmental input (in this case, the spatially demanding task of driving a cab all over London). That hard-won neuroplasticity required years of mental and physical practice. Wouldn’t it be nice to get the same effects without so much work?

    To hear some people tell it, you can: Psychedelic drugs such as psilocybin, LSD, ayahuasca, and Ecstasy, along with anesthetics such as ketamine, can enhance a user’s neuroplasticity within hours of administration. In fact, some users take psychedelics for the express purpose of making their brain a little more malleable. Just drop some acid, the thinking goes, and your brain will rewire itself—you’ll be smarter, fitter, more creative, and self-aware. You might even get a transcendent experience. Popular media abound with anecdotes suggesting that microdosing LSD or psilocybin can expand divergent thinking, a more free and associative type of thinking that some psychologists link with creativity.

    Research suggests that psychedelic-induced neuroplasticity can indeed enhance specific types of learning, particularly in terms of overcoming fear and anxiety associated with past trauma. But claims about the transformative, brain-enhancing effects of psychedelics are, for the most part, overstated. We don’t really know yet how much microdosing, or a full-blown trip, will change the average person’s mental circuitry. And there’s reason to suspect that, for some people, such changes may be actively harmful.

    There is nothing new about the notion that the human and animal brain are pliant in response to everyday experience and injury. The philosopher and psychologist William James is said to have first used the term plasticity back in 1890 to describe changes in neural pathways that are linked to the formation of habits. Now we understand that these changes take place not only between neurons but also within them: Individual cells are capable of sprouting new connections and reorganizing in response to all kinds of experiences. Essentially, this is a neural response to learning, which psychedelics can rev up.

    We also understand how potent psychedelic drugs can be in inducing changes to the brain. Injecting psilocybin into a mouse can stimulate neurons in the frontal cortex to grow by about 10 percent and sprout new spines, projections that foster connections to other neurons. It also alleviated their stress-related behaviors—effects that persisted for more than a month, indicating enduring structural change linked with learning. Presumably, a similar effect takes place in humans. (Comparable studies on humans would be impossible to conduct, because investigating changes in a single neuron would require, well, sacrificing the subject.)

    The thing is, all those changes aren’t necessarily all good. Neuroplasticity just means that your brain—and your mind—is put into a state where it is more easily influenced. The effect is a bit like putting a glass vase back into the kiln, which makes it pliable and easy to reshape. Of course you can make the vase more functional and beautiful, but you might also turn it into a mess. Above all else, psychedelics make us exquisitely impressionable, thanks to their speed of action and magnitude of effect, though their ultimate effect is still heavily dependent on context and influence.

    We have all experienced heightened neuroplasticity during the so-called sensitive periods of brain development, which typically unfold between the ages of 1 and 4 when the brain is uniquely responsive to environmental input. This helps explain why kids effortlessly learn all kinds of things, like how to ski or speak a new language. But even in childhood, you don’t acquire your knowledge and skills by magic; you have to do something in a stimulating enough environment to leverage this neuroplastic state. If you have the misfortune of being neglected or abused during your brain’s sensitive periods, the effects are likely to be adverse and enduring—probably more so than if the same events happened later in life.

    Being in a neuroplastic state enhances our ability to learn, but it might also burn in negative or traumatic experiences—or memories—if you happen to have them while taking a psychedelic. Last year, a patient of mine, a woman in her early 50s, decided to try psilocybin with a friend. The experience was quite pleasurable until she started to recall memories of her emotionally abusive father, who had an alcohol addiction. In the weeks following her psilocybin exposure, she had vivid and painful recollections of her childhood, which precipitated an acute depression.

    Her experience might have been very different—perhaps even positive—if she’d had a guide or therapist with her while she was tripping to help her reappraise these memories and make them less toxic. But without a mediating positive influence, she was left to the mercy of her imagination. This must have been just the sort of situation legislators in Oregon had in mind last month when they legalized recreational psilocybin use, but only in conjunction with a licensed guide. It’s the right idea.

    In truth, researchers and clinicians haven’t a clue whether people who microdose frequently with psychedelics—and are thus walking around in a state of enhanced neuroplasticity—are more vulnerable to the encoding of traumatic events. In order to find out, you would have to compare a group of people who microdose against a group of people who don’t over a period of time and see, for example, if they differ in rates of PTSD. Crucially, you’d have to randomly assign people to either microdose or abstain—not simply let them pick whether they want to try tripping. In the absence of such a study, we are all currently involved in a large, uncontrolled social experiment. The results will inevitably be messy and inconclusive.

    Even if opening your brain to change were all to the good, the promise of neuroplasticity without limit—that you can rejuvenate and remodel the brain at any age—far exceeds scientific evidence. Despite claims to the contrary, each of us has an upper limit to how malleable we can make our brain. The sensitive periods, when we hit our maximum plasticity, is a finite window of opportunity that slams shut as the brain matures. We progressively lose neuroplasticity as we age. Of course we can continue to learn—it just takes more effort than when we were young. Part of this change is structural: At 75, your hippocampus contains neurons that are a lot less connected to one another than they were at 25. That’s one of the major reasons older people find that their memory is not as sharp as it used to be. You may enhance those connections slightly with a dose of psilocybin, but you simply can’t make your brain behave as if it’s five decades younger.

    This reality has never stopped a highly profitable industry from catering to people’s anxieties and hopes—especially seniors’. You don’t have to search long online before you find all kinds of supplements claiming to keep your brain young and sharp. Brain-training programs go even further, purporting to rewire your brain and boost your cognition (sound familiar?), when in reality the benefits are very modest, and limited to whatever cognitive task you’ve practiced. Memorizing a string of numbers will make you better at memorizing numbers; it won’t transfer to another skill and make you better at, say, chess.

    We lose neuroplasticity as we age for good reason. To retain our experience, we don’t want our brain to rewire itself too much. Yes, we lose cognitive fluidity along the way, but we gain knowledge too. That’s not a bad trade-off. After all, it’s probably more valuable to an adult to be able to use all of their accumulated knowledge than to be able to solve a novel mathematical problem or learn a new skill. More important, our very identity is encoded in our neural architecture—something we wouldn’t want to tinker with lightly.

    At their best, psychedelics and other neuroplasticity-enhancing drugs can do some wonderful things, such as speed up the treatment of depression, quell anxiety in terminally ill patients, and alleviate the worst symptoms of PTSD. That’s enough reason to research their uses and let patients know psychedelics are an option for psychiatric treatment when the evidence supports it. But limitless drug-induced self-enhancement is simply an illusion.

    [ad_2]

    Richard A. Friedman

    Source link

  • Facing Death Without Fear: Psychedelics for End-of-Life Care

    Facing Death Without Fear: Psychedelics for End-of-Life Care

    [ad_1]

    For Christine “Cat” Parlee, who has stage IV metastatic melanoma, the Roots to Thrive program was a godsend. Not that she expects it to save her life: The probability of surviving advanced melanoma for 5 years is about 15%-20%, according to the American Cancer Society, and Parlee was diagnosed in 2017. But an innovative approach to group therapy at Roots to Thrive, based in Nanaimo, British Columbia, has helped her deal with this life-threatening disease.

    Parlee’s health issues are complex. As if malignant skin cancer wasn’t enough, the 50-something resident of Vancouver Island also has a condition called trigeminal neuralgia with anesthesia dolorosa. With that rare disorder, she says, “emotional outbursts can literally cause me severe pain. So I got very good at suppressing my emotions.” 

    “But you don’t grow, or grieve, or eventually accept the end if you don’t process your fears,” she continues. Roots to Life has “allowed me to experience my own anger, fear – the feeling that this is SO unfair – without pain or panic attacks. … It’s one of the hardest yet most beautiful experiences I have ever had to put in words.”

    A key ingredient of that experience is psilocybin, aka magic mushrooms. Founded in 2019, the nonprofit Roots to Thrive is the first Canadian medical practice to legally use psychedelic drugs, specifically psilocybin and ketamine, in group therapy for patients facing the end of life. Combined with two other ingredients – a psychotherapist and a supportive patient community – the drugs have proved highly effective in easing the distress that comes with a terminal diagnosis, according to Pamela Kryskow, MD, the medical lead at Roots to Thrive.

    “Once that safe community is built, a psilocybin mushroom session with that same group of people creates a healing container, where patients can deeply explore their challenges while under the influence of the medicine,” says Kryskow, who is also a clinical instructor at the University of British Columbia and adjunct professor at Vancouver Island University.

    “Once that safe community is built, a psilocybin mushroom session with that same group of people creates a healing container, where patients can deeply explore their challenges while under the influence of the medicine,” says Kryskow, who is also a clinical instructor at the University of British Columbia and adjunct professor at Vancouver Island University.

    Clinical Trials at Full Tilt

    Research confirms the promise of psychedelics – from plant-based psilocybin and DMT to synthetic MDMA (ecstasy) and LSD – for palliative and end-of-life patients. In 2016, a landmark study at NYU Grossman School of Medicine found that a single dose of psilocybin relieved depression, anxiety, and hopelessness in cancer patients. More recently, in a follow-up study, 80% of the same patients reported that the positive effects were sustained 4½ years later. And more testing is in progress.

    “There are 113 clinical trials currently registered at clinicaltrials.gov,” says Paul Stamets, a mycologist whose 2020 book Fantastic Fungi is a companion to a popular Netflix documentary. “This is unprecedented, and a reflection of the scientific justification for exploring the benefits of psilocybin over a wide range of mental health issues.”

    That exploration dates back to the 1950s, when psychiatrists like Humphry Osmond, who coined the word “psychedelic,” first experimented with LSD-assisted psychotherapy. Studies during that period were less than rigorous by today’s standards, however, and in the United States they virtually came to a halt with the 1970 signing of the Controlled Substances Act. But decades later, in 2014, Scientific American called for an end to the ban on clinical trials involving psychedelics. By then, the country was in the middle of what psychiatrist Ben Sessa dubbed a “psychedelic renaissance.”

    Right-to-try laws, which give gravely ill patients access to experimental drugs without having to wait for FDA approval, have helped jump-start the surge in psychedelic research. Currently, 41 states have their own versions of these statutes, which stand alongside the federal Right to Try Act, signed into law in 2018. Two states have focused on psilocybin in particular. In 2020, Oregon became the first to legalize the therapeutic use of psychedelic mushrooms. Colorado voters recently followed suit, decriminalizing magic mushrooms on Election Day 2022. This is expected to pave the way for similar changes in Colorado laws that prohibit other plant-based psychedelics, such as DMT, ibogaine, and certain forms of mescaline, in June 2026.

    How Psychedelics Work

    As defined by the National Institutes of Health, psychedelics are potent psychoactive substances that alter cognition, changing the user’s mood and perceptions by acting on neutral circuits in the brain that involve the chemical serotonin. Much of this happens in the prefrontal cortex, the part of the brain that regulates how you feel and how you see the world. “Psychedelic drugs, including psilocybin, are believed to all act on what are called serotonin 2A receptors,” explains Charles Nemeroff, MD, PhD, chair of the Department of Psychiatry and Behavioral Sciences and co-director of the Center for Psychedelic Research and Therapy at the University of Texas’s Dell Medical School in Austin.

    Matthew W. Johnson, PhD, a professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine in Baltimore, describes the activation of the subtype of serotonin receptor as “the first step in the chain,” one that leads to “changes in brain communication” during the psychedelic experience. “It’s likely that the brain looks different in the long term in a way that corresponds to psychological and behavioral improvements,” he says, noting that psilocybin “works more like psychotherapy than other psychiatric meds.”

    However, psychedelics work, they have been shown under certain circumstances to be an effective complement to psychological support for end-of-life patients. In a recent study of more than 3,000 adults, the Johns Hopkins Center for Psychedelic and Consciousness Research found that taking these drugs under the right conditions made people less afraid of death, much the way a near-death experience unrelated to drugs may reduce the fear of mortality. The result, of course, can be a dramatic improvement in quality of life for the terminally ill. 

    This isn’t to suggest that psychedelics are a panacea. Johnson notes, for example, that the therapy is especially risky for patients with schizophrenia or severe heart disease. Gauging the risks calls for further research, says Gregory A. Fonzo, PhD, an assistant professor and co-director of the Center for Psychedelic Research and Therapy in the Department of Psychiatry and Behavioral Sciences at Dell Medical School. “Current studies have focused primarily on establishing efficacy,” he points out. “But future studies with larger numbers of participants are necessary in order to identify individuals who are likely­ – and not likely – to respond well to this treatment.”

    Separating the Patient From the Diagnosis

    For those who respond well to psychedelic therapy, it isn’t just an individual experience. “Many patients report breakthroughs in family dynamics,” says Johnson. In some cases, this happens as “they start having more open conversations about potential or pending death.”

    There have been other kinds of breakthroughs as well. “We’ve heard many reports of profound insights, transpersonal experiences, and rapid shifts in patients’ moods and their sense of self occurring during psychedelic experiences,” Fonzo says. “It’s possible that these patients’ subsequent changes in their belief systems, their perceptions of self and others, and their overall mood state are key factors that promote benefits for conditions such as depression. But additional research is needed to validate that.”

    Clinical trials have even dipped into the realm of spirituality. In 2021, a Johns Hopkins review of psychedelic research focusing on end-of-life and palliative care noted that some psilocybin studies used a mystical experience questionnaire designed to measure things like “a sense of unity, reverence, and authoritative truth … transcendence of time/space, and ineffability.”

    But for many end-of-life patients, one of the most important benefits of the therapy is more concrete: They come to see themselves as separate from their diagnosis. “These sessions typically lead to changed narratives that a person carries about the cancer and themselves,” Johnson says. “I think these patients are actually learning things about themselves and about life, and that’s what separates psilocybin from other psychiatric medications.” 

    In helping terminal patients overcome the fear of death, psychedelic therapy often frees them, paradoxically, to live more fully. “[Patients] say that they have healed old traumas they’ve carried, so they are able to be more present with their family and friends,” Kryskow says. “They are able to focus on having more fun and more connection.” 

    Still, results vary, and Cat Parlee maintains that each psychedelic experience is unique. “Mine changed me to the very core of my DNA,” she says. Before she signed up for Roots to Thrive, she says, “the very thought of death caused me to have massive panic attacks.” But those days are gone. Her advice to prospective patients considering a similar program: “Be open. Be vulnerable. And no matter what you’ve heard, leave your expectations at the door.”

    [ad_2]

    Source link

  • Colorado Says Yes to Medical Use of ‘Magic Mushrooms’

    Colorado Says Yes to Medical Use of ‘Magic Mushrooms’

    [ad_1]

    By Cara Murez 

    HealthDay Reporter

    MONDAY, Nov. 14, 2022 (HealthDay News) – Colorado voters have voted narrowly to approve the medical use of “magic mushrooms” in Colorado.

    “I’m in awe of what we were able to accomplish,” said Veronica Lightning Horse Perez, a lead proponent for legalizing psilocybin, the main psychoactive compound in mushrooms. “Over a million people voted yes on this. To think that many people see the value in these medicines, that many people know that these can be used for healing — that’s huge.”

    In 2018, the U.S. Food and Drug Administration called psilocybin a “breakthrough therapy,” which has sped up development of medications using the compound.

    Psilocybin may have potential as a treatment for a host of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), drug dependency and eating disorders. Clinical trials to further research this are continuing.

    A movement to legalize psilocybin is growing: Oregon voters approved allowing its therapeutic use in 2020, while it has been decriminalized in Washington, D.C. and more than a dozen additional cities, NBC News reported.

    An additional 19 states have seen the introduction of bills to legalize its possession, though none have been approved yet. These include Missouri, Iowa and Kansas. More than a dozen other states are seeking to further study its health benefits, including Florida, NBC News reported.

    Meanwhile, Hawaii’s state Senate has approved assembling a task force that would plan for making the drug available to adults as a mental health treatment. Connecticut has adjusted its state budget to fund programs that would use the drug in working with veterans and retired first responders.

    In Oklahoma’s House of Representatives, a bill to authorize scientific research into psilocybin is headed to the Senate. It would allow state-run clinical trials for adults with specific conditions, NBC News reported.

    “More folks are starting to recognize and understand, when it comes to psychedelic therapy, this is not some sort of radical field. It’s becoming more mainstream,” Oklahoma state Rep. Daniel Pae, who co-authored the bill, told NBC News.

    Texas has already passed a similar bill to study the drug.

    Meanwhile, psilocybin remains illegal at the federal level and in most states, NBC News reported.

    Importantly, the new Colordao law does not allow retail sales or use in various circumstances, including schools, in public or while operating a vehicle.

    Denver-based addiction counselor Kevin Franciotti told NBC News that the measure gives Colorado the “opportunity to be a leader in pushing American drug policy in the right direction.”

    Still, opponents of the Colorado measure called for not jumping ahead of FDA approval.

    “I’m hoping the rest of the country can learn the hard lessons from my state’s foray,” Luke Niforatos, who leads two national organizations that opposed the measure. “As the years go on and we learn more about this experiment, hopefully we’ll say we’re going to let the FDA and scientists lead medicine, not corporations.”

    More information

    The National Library of Medicine has more on psilocybin as a therapeutic.

     

     

    SOURCE: NBC News

    [ad_2]

    Source link

  • Does Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen Investigates

    Does Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen Investigates

    [ad_1]

    Press Release


    Sep 15, 2022

    The Microdosing and Meditation Study, led by Beckley Foundation in collaboration with Psychedelic Data Society and Quantified Citizen (QC), seeks to observe how meditation skills evolve over three months of regular meditation practice and whether, how, and for whom microdosing (the repeated use of low sub-perceptual doses of psychedelics) may impact these skills.

    ‘Enhancing Mindfulness’ was reported as the most widely endorsed motivation for microdosing (Rootman et al., 2021) in the largest microdosing study to date, Microdose.me, which was conducted by Quantified Citizen in collaboration with University of British Columbia and Maastricht University. The study was launched in 2019 and is still running with over 20,000 participants to date. Despite the growing evidence of overlap between the neurophysiology and phenomenology of psychedelic drug-induced states and contemplative practices, no research to date has specifically assessed the effect of microdosing on meditation practice. 

    “In my opinion, psychedelics can be used as tools to get into a higher state of awareness, which, rather like a farmer preparing the ground for seeding, can help achieve a more fertile ground for either meditation or creative thinking. No research has been conducted so far on the effect of microdosing on meditation practice, and I am very curious to find out if regular meditators do experience measurable benefits from microdosing,” shares Amanda Feilding, director of the Beckley Foundation. 

    The results of this study will help guide future research and improve understanding of the effects of microdosing. Ideally, this will lead to better safety and insight into potential benefits and risk factors.

    Why should you participate?

    This study will help you (whether you use psychedelics or not) engage in a useful self-reflexive process, where you can evaluate, through a protocol carefully designed by a psychology researcher and meditation expert, the ways in which your meditation practice evolves over time, and whether, and in what way, microdosing interacts with this practice. You may also help increase the current scientific understanding of the effects of psychedelic microdosing on meditation.

    Who can participate?

    The study will gather data from all meditation practitioners, whether or not they use psychedelics. 

    How to participate

    To join, please enroll in the Microdose.me study on the Quantified Citizen app. Microdose.me shares standardized assessments with the Microdosing and Meditation Study to avoid repetition. After this first step, you will unlock the Microdosing and Meditation onboarding process.

    Quantified Citizen is a citizen science-powered health research app. It has a growing library of studies on interventions, techniques and emerging trends.

    To fuel further growth and development of new study capabilities, Quantified Citizen is currently in the process of raising its Seed+ round of funding.

    Investor Contact:

    Eesmyal Santos-Brault, Co-founder & CEO

    invest@quantifiedcitizen.com, +1-604-800-2911

    Press Contact:

    Nikki Paqueo, Product Marketing Manager

    marketing@quantifiedcitizen.com, +1-604-800-2911

    Source: Quantified Citizen

    [ad_2]

    Source link